Zevra Therapeutics
ZVRA
30 hedge funds and large institutions have $23.4M invested in Zevra Therapeutics in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 3 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
6% less funds holding
Funds holding: 32 → 30 (-2)
22% less capital invested
Capital invested by funds: $30.1M → $23.4M (-$6.61M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
71% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 14
Top Buyers
| 1 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$823K |
| 2 |
SIM
Spark Investment Management
New York
|
+$95.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.9K |
| 4 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$3.16K |
| 5 |
Barclays
London,
United Kingdom
|
+$1.25K |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$1.56M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$210K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$88.7K |
| 4 |
Millennium Management
New York
|
-$73K |
| 5 |
BlackRock
New York
|
-$40.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
26
Advisor Group
Phoenix,
Arizona
| $4K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $3K | -$3.1K | -47 | -47% |
|
28
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2K | -$132 | -2 | -7% |
|
|
29
Barclays
London,
United Kingdom
| $1K | +$1.25K | +19 | +317% |
|
|
30
Millennium Management
New York
| – | -$73K | -936 | Closed |
|
31
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$7K | -96 | Closed |
|
32
JP Morgan Chase
New York
| – | -$2K | -31 | Closed |
|
ZVRA Hedge Fund Activity: Q2 2017 in Review
30 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2017, worth a combined $23.4M — down 22% from $30.1M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ZVRA and 1 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 4 added.
The largest buyer was C WorldWide Group, adding an estimated $823K. The largest seller was Deerfield Management, cutting an estimated $1.56M.
- 30 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2017, down from 32 in Q1 2017.
- Funds reported $23.4M of Zevra Therapeutics stock for Q2 2017, down 22% quarter-over-quarter.
- 1 fund opened new Zevra Therapeutics positions in Q2 2017 and 3 closed out, a net change of -2 holders.
- The largest Zevra Therapeutics buyer in Q2 2017 was C WorldWide Group, an estimated $823K added.
- The largest Zevra Therapeutics seller in Q2 2017 was Deerfield Management, an estimated $1.56M sold.
Based on aggregated 13F filings for Q2 2017.